SCHEMBL5555946

SCHEMBL5555946

N#Cc1ccc(-c2cc(=O)[nH]cc2C#N)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 5/20 0.44
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
MAOB P27338 1/20 0.39
GALR3 O60755 1/20 0.39
GAA P10253 1/20 0.39
STS P08842 1/20 0.38
HSP90AB1 P08238 1/20 0.38
LRRK2 Q5S007 2/20 0.38
IDO1 P14902 1/20 0.38
NOTUM Q6P988 1/20 0.37
PRKAB2 O43741 1/20 0.37
PRKAG1 P54619 1/20 0.37
PRKAA2 P54646 1/20 0.37
PRKAA1 Q13131 1/20 0.37
PRKAG3 Q9UGI9 1/20 0.37
PRKAG2 Q9UGJ0 1/20 0.37
PRKAB1 Q9Y478 1/20 0.37
TNKS O95271 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5556155 0.86 MCL1 (0.56) MCL1KDM4EALDH1A1HPGDGALR3
SCHEMBL5562294 0.85 LRRK2 (0.50) MCL1KDM4EALDH1A1HPGDMAOB
SCHEMBL5556561 0.85 MCL1 (0.56) MCL1KDM4EALDH1A1HPGDGAA
SCHEMBL5556242 0.84 XDH (0.49) MCL1KDM4EALDH1A1HPGDMAOB
SCHEMBL5556167 0.83 GABRA1 (0.46) MCL1KDM4EALDH1A1HPGDGALR3
SCHEMBL5556347 0.81 PRKAB2 (0.55) KDM4EALDH1A1MAOBGAALRRK2
SCHEMBL5561835 0.73 LRRK2 (0.59) KDM4EALDH1A1HPGDGAALRRK2
SCHEMBL10796898 0.73 CYP11B2 (0.42) ALDH1A1STSHSP90AB1
SCHEMBL5561047 0.72 LRRK2 (0.52) MCL1KDM4EALDH1A1HPGDGAA
SCHEMBL16115949 0.72 KDM4E (0.46) MCL1KDM4EALDH1A1HPGDLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656351-B1 PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-12-19 EP claimed
EP-1656351-A1 PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-05-17 EP claimed
WO-2005014549-A1 PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES F. HOFFMANN-LA-ROCHE AG (CH) 2005-02-17 WO claimed
US-20050014792-A1 Process for preparation of pyridine derivatives ROCHE PALO ALTO LLC 2005-01-20 US claimed
EP-1656351-B1 PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-12-19 EP disclosed
US-7288658-B2 Process for preparation of pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2007-10-30 US disclosed
EP-1656351-A1 PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-05-17 EP disclosed
WO-2005014549-A1 PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES F. HOFFMANN-LA-ROCHE AG (CH) 2005-02-17 WO disclosed
US-20050014792-A1 Process for preparation of pyridine derivatives ROCHE PALO ALTO LLC 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014792-A1 Process for preparation of pyridine derivatives NOX3, KMO, PBK MCL1 780/4885KDM4E 1175/4885ALDH1A1 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.